The value of an artificial neural network in the decision-making for prostate biopsies

World Journal of Urology

Volumn 27, Issue 5, 2009, Pages 593-598

  Meijer, R P ^a   Gemen, E F A ^a   van Onna, I E W ^b   van der Linden, J C ^a   Beerlage, H P ^a   Kusters, G C M ^a  

^a JEROEN BOSCH HOSPITAL   (Netherlands)

^b AMPHIA HOSPITAL   (Netherlands)

Author keywords

Artificial neural network; Prostate biopsy; Prostate cancer

Indexed keywords

AGED; ARTICLE; ARTIFICIAL NEURAL NETWORK; BIOPSY; DECISION SUPPORT SYSTEM; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE; PROSTATE TUMOR;

AGED; AGED, 80 AND OVER; BIOPSY; DECISION MAKING, COMPUTER-ASSISTED; HUMANS; MALE; MIDDLE AGED; NEURAL NETWORKS (COMPUTER); PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS;

EID: 70349515350     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-009-0444-7     Document Type: Article

References (25)

1. Partin AW, Oesterling JE (1994) The clinical usefulness of prostate specific antigen: Update 1994. J Urol 152:1358-1368
2. Polascik TJ, Oesterling JE, Partin AW (1999) Prostate specific antigen: a decade of discovery-what we have learned and where we are going. J Urol 162:293-306
3. Beduschi MC, Oesterling JE (1997) Prostate-specific antigen density. Urol Clin North Am 24:323-332
4. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A et al (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 279:1542-1547
5. Carter HB, Pearson JD (1997) Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Urol Clin North Am 24:333-338
6. Nixon RG, Brawer MK (1997) Enhancing the specificity of prostate-specific antigen (PSA): An overview of PSA density, velocity and age-specific reference ranges. Br J Urol 79(Suppl 1):61-67
7. Lee R, Localio AR, Armstrong K, Malkowicz SB, Schwartz JS (2006) A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology 67:762-768
8. Okihara K, Cheli CD, Partin AW, Fritche HA, Chan DW, Sokoll LJ et al (2002) Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol 167:2017-2023
9. Gann PH, Ma J, Catalona WJ, Stampfer MJ (2002) Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: A prospective evaluation. J Urol 167:2427-2434
10. Stephan C, Jung K, Cammann H, Vogel B, Brux B, Kristiansen G et al (2002) An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: Results of a 5-year investigation. Int J Cancer 99:466-473
11. Matsui Y, Utsunomiya N, Ichioka K, Ueda N, Yoshimura K, Terai A et al (2004) The use of artificial neural network analysis to improve the predictive accuracy of prostate biopsy in the Japanese population. Jpn J Clin Oncol 34:602-607
12. Virtanen A, Gomari M, Kranse R, Stenman UH (1999) Estimation of prostate cancer probability by logistic regression: Free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. Clin Chem 45:987-994
13. Finne P, Finne R, Bangma C, Hugosson J, Hakama M, Auvinen A et al (2004) Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening. Int J Cancer 111:310-315
14. Remzi M, Anagnostou T, Ravery V, Zlotta AR, Stephan C, Marberger M et al (2003) An artificial neural network to predict the outcome of repeat prostate biopsies. Urology 62:456-460
15. Stephan C, Cammann H, Meyer HA, Lein M, Jung K (2007) PSA and new biomarkers within multivariate models to improve early detection of prostate cancer. Cancer Lett 249:18-29
16. Montie JE, Wei JT (2000) Artificial neural networks for prostate carcinoma risk assessment: An overview. Cancer 88:2655-2660
17. Chun FK, Graefen M, Briganti A, Gallina A, Hopp J, Kattan MW et al (2007) Initial biopsy outcome prediction-head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol 51:1236-1240
18. Kawakami S, Numao N, Okubo Y, Koga F, Yamamoto S, Saito K et al (2008) Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy. Eur Urol 54:601-611
19. Wei JT, Zhang Z, Barnhill SD, Madyastha KR, Zhang H, Oesterling JE (1998) Understanding artificial neural networks and exploring their potential applications for the practicing urologist. Urology 52:161-172
20. Dayhoff JE, DeLeo JM (2001) Artificial neural networks: Opening the black box. Cancer 91:1615-1635
21. Anagnostou T, Remzi M, Djavan B (2003) Artificial neural networks for decision-making in urologic oncology. Rev Urol 5:15-21
22. Stephan C, Cammann H, Semjonow A, Diamandis EP, Wymenga LF, Lein M et al (2002) Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem 48:1279-1287
23. Djavan B, Remzi M, Zlotta AR, Seitz C, Snow P, Marberger M (2002) Novel artificial neural network for early detection of prostate cancer. J Clin Oncol 20:921-929
24. Zlotta AR, Remzi M, Snow PB, Schulman CC, Marberger M, Djavan B (2003) An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng/ml or less. J Urol 169:1724-1728
25. Babaian RJ, Fritsche H, Ayala A, Bhadkamkar V, Johnston DA, Naccarato W et al (2000) Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/ mL. Urology 56:1000-1006